Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Lifecycle modelling systems support inosine monophosphate dehydrogenase (IMPDH) as a pro-viral factor and antiviral target for New World arenaviruses.

Dunham EC, Leske A, Shifflett K, Watt A, Feldmann H, Hoenen T, Groseth A.

Antiviral Res. 2018 Sep;157:140-150. doi: 10.1016/j.antiviral.2018.07.009. Epub 2018 Jul 19.

PMID:
30031760
2.

Gateways to clinical trials.

Tomillero A, Moral MA.

Methods Find Exp Clin Pharmacol. 2009 Mar;31(2):107-46.

PMID:
19455266
3.

Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin.

Huang M, Itahana K, Zhang Y, Mitchell BS.

Cancer Res. 2009 Apr 1;69(7):3004-12. doi: 10.1158/0008-5472.CAN-08-3413. Epub 2009 Mar 24.

4.

A phase I dose-ranging study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of AVN944, an IMPDH inhibitor, in healthy male volunteers.

Hamilton JM, Harding MW, Genna T, Bol DK.

J Clin Pharmacol. 2009 Jan;49(1):30-8. doi: 10.1177/0091270008325149. Epub 2008 Oct 29.

PMID:
18971325
5.

Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells.

Floryk D, Thompson TC.

Int J Cancer. 2008 Nov 15;123(10):2294-302. doi: 10.1002/ijc.23788.

6.

Recent development of IMP dehydrogenase inhibitors for the treatment of cancer.

Chen L, Pankiewicz KW.

Curr Opin Drug Discov Devel. 2007 Jul;10(4):403-12. Review.

PMID:
17659481
7.

Guanine nucleotide depletion inhibits pre-ribosomal RNA synthesis and causes nucleolar disruption.

Huang M, Ji Y, Itahana K, Zhang Y, Mitchell B.

Leuk Res. 2008 Jan;32(1):131-41. Epub 2007 Apr 25.

Supplemental Content

Loading ...
Support Center